{"id":"paliperidone-clozapine","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Extrapyramidal symptoms (akathisia, dystonia, parkinsonism)"},{"rate":"15-30","effect":"Weight gain"},{"rate":"10-25","effect":"Metabolic syndrome (hyperglycemia, dyslipidemia)"},{"rate":"20-40","effect":"Sedation"},{"rate":"5-15","effect":"Orthostatic hypotension"},{"rate":"0.5-1","effect":"Agranulocytosis (clozapine-specific)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both agents are second-generation antipsychotics that antagonize dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis. They also block serotonin 5-HT2A receptors, which may enhance dopamine release in the prefrontal cortex and improve negative and cognitive symptoms. Clozapine has additional activity at muscarinic and histamine receptors, contributing to its unique clinical profile.","oneSentence":"Paliperidone and clozapine are atypical antipsychotics that block dopamine D2 and serotonin 5-HT2A receptors to reduce psychotic symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:35:37.683Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Schizoaffective disorder"},{"name":"Bipolar disorder (acute agitation)"}]},"trialDetails":[{"nctId":"NCT05741502","phase":"PHASE4","title":"An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2023-08-16","conditions":"Treatment-resistant Schizophrenia","enrollment":5},{"nctId":"NCT07047651","phase":"PHASE4","title":"Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.","status":"RECRUITING","sponsor":"Dr. Stavroula Rakitzi","startDate":"2025-06-04","conditions":"Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder","enrollment":40},{"nctId":"NCT04002700","phase":"","title":"A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-05-06","conditions":"Stroke","enrollment":1234412},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT06040944","phase":"","title":"Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2022-09-01","conditions":"Schizophrenia Spectrum and Other Psychotic Disorders, Periodontal Diseases","enrollment":64},{"nctId":"NCT01498770","phase":"","title":"An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-04-01","conditions":"Bipolar Disorder","enrollment":42},{"nctId":"NCT02213887","phase":"PHASE4","title":"Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications","status":"WITHDRAWN","sponsor":"University of British Columbia","startDate":"2014-09","conditions":"Psychotic Disorders, Gastroesophageal Reflux","enrollment":""},{"nctId":"NCT03565068","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-20","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":"Schizophrenia","enrollment":174},{"nctId":"NCT02181803","phase":"PHASE1","title":"MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-05","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT02248987","phase":"","title":"Study on Abnormal Dopamine Synthesis and Connectivity According to the Antipsychotic Treatment Response in Schizophrenia","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-05","conditions":"Schizophrenia","enrollment":36},{"nctId":"NCT02600741","phase":"","title":"Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-24","conditions":"Schizophrenia","enrollment":296},{"nctId":"NCT02307396","phase":"PHASE4","title":"Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-02-01","conditions":"Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders","enrollment":21},{"nctId":"NCT02529163","phase":"NA","title":"Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms","status":"UNKNOWN","sponsor":"Centre for Addiction and Mental Health","startDate":"2015-08","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":24},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT02582736","phase":"","title":"Antipsychotics and Risk of Hyperglycemic Emergencies","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2012-04","conditions":"Psychotic Disorders, Schizophrenia, Schizoaffective Disorder","enrollment":725489},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":"Psychosis Nos/Other","enrollment":104},{"nctId":"NCT01323205","phase":"PHASE2","title":"Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-05","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT00704860","phase":"PHASE4","title":"Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism","status":"COMPLETED","sponsor":"University of Ottawa","startDate":"2005-02","conditions":"Major Depression","enrollment":27},{"nctId":"NCT01279213","phase":"PHASE4","title":"Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia","status":"COMPLETED","sponsor":"Universidad Nacional de Rosario","startDate":"2009-01","conditions":"Schizophrenia, Schizophrenic Disorders, Psychotic Disorder","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":278,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"paliperidone clozapine","genericName":"paliperidone clozapine","companyName":"Universidad Nacional de Rosario","companyId":"universidad-nacional-de-rosario","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Paliperidone and clozapine are atypical antipsychotics that block dopamine D2 and serotonin 5-HT2A receptors to reduce psychotic symptoms. Used for Schizophrenia, Schizoaffective disorder, Bipolar disorder (acute agitation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}